Project outline

Sodium-glucose co-transporter-2 (SGLT2) inhibitors are established oral glucose-lowering medications for the treatment of type 2 diabetes. In recent years, these drugs have drawn considerable attention for their protective effects on the heart and kidneys. The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study was the first completed large randomised controlled trial to demonstrate that an SGLT2 inhibitor, canagliflozin, significantly reduces the risk of kidney failure and cardiovascular events in people with type 2 diabetes and established chronic kidney disease. However, little is known about the generalisability of the trial to people with type 2 diabetes in the real-world. 

How does this research try to address the problem?

Using the Oxford-Royal College of General Practitioners Clinical Informatics Digital Hub (ORCHID) database, we will calculate the percentage of people with type 2 diabetes in the Oxford-RCGP RSC network with an equivalent risk profile for serious kidney events as defined in the CREDENCE trial eligibility criteria. We will also describe the demographic and clinical characteristics of this real-world population and compare it to participants in the CREDENCE trial. 

How we are planning to implement the research outputs 

Findings from the study will be submitted for publication in a peer reviewed journal..

How were the patient and public involved? 

We have involved patients living with diabetes in the development of this study. We plan to disseminate the findings to this group. We will work together to produce information using language and formats readily understood by a lay audience.